Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma
Overall, we report that Sitagliptin and Linagliptin have significant anticancer potential towards KRAS-mutated PDAC. Furthermore, we recommend repurposing of more drugs to examine their anti-cancer potential towards these aggressive cancers and to overcome clinical resistance in the near future.
Authors
- Gothandam Kodiveri Muthukaliannan (ORCID: https://orcid.org/0000-0003-1576-5324)
- M. Janaki Ramaiah (ORCID: https://orcid.org/0000-0003-1814-2819)
- T. Premkumar (ORCID: https://orcid.org/0009-0006-0651-8259)
- Gayathri Chellasamy (ORCID: https://orcid.org/0000-0002-2291-3594)
- Divya Sharma (ORCID: https://orcid.org/0009-0004-3376-0847)
- Prasanna Srinivasan Ramalingam (ORCID: https://orcid.org/0000-0002-8281-2779)
- Salman Alrokayan (ORCID: https://orcid.org/0000-0002-0120-0309)
- Purushothaman Balakrishnan
- Md Sadique Hussain (ORCID: https://orcid.org/0000-0002-3554-1750)
- Rudra Awdhesh Kumar Mishra (ORCID: https://orcid.org/0000-0002-9508-5320)
- Tajamul Hussain (ORCID: https://orcid.org/0000-0001-7601-1417)
- Sivakumar Arumugam (ORCID: https://orcid.org/0000-0001-8834-8834)
- Sujatha Elangovan (ORCID: https://orcid.org/0000-0003-3400-9874)
Institutions
- Central University of Tamil Nadu (IN)
- Gachon University (KR)
- King Saud University (SA)
- Uttaranchal University (IN)
- Vellore Institute of Technology University (IN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1186/s40360-025-01020-z
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- National Research Foundation
- King Saud University
- Gachon University
- National Research Foundation of Korea
- VIT University